These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24086104)

  • 1. Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes.
    Hauber AB; Han S; Yang JC; Gantz I; Tunceli K; Gonzalez JM; Brodovicz K; Alexander CM; Davies M; Iglay K; Zhang Q; Radican L
    Patient Prefer Adherence; 2013; 7():937-49. PubMed ID: 24086104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus.
    Hauber AB; Tunceli K; Yang JC; Gantz I; Brodovicz KG; Alexander CM; Davies MJ; Radican L
    Diabetes Ther; 2015 Mar; 6(1):75-84. PubMed ID: 25586555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
    Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
    Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment.
    Panchal R; Nguyen D; Ghule P; Li N; Giannouchos T; Pan RJ; Biskupiak J; Britton L; Nohavec R; Slager S; Ngorsuraches S; Brixner D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):139-150. PubMed ID: 36705280
    [No Abstract]   [Full Text] [Related]  

  • 5. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
    Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
    Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the Preferences and Willingness-to-Pay for Oral Antidiabetic Drugs Among Patients with Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment.
    Chuang LH; Zhang H; Hong T; Xie S
    Patient; 2024 Sep; 17(5):565-574. PubMed ID: 38642244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding patient preferences and willingness to pay for hemophilia therapies.
    Chaugule SS; Hay JW; Young G
    Patient Prefer Adherence; 2015; 9():1623-30. PubMed ID: 26635471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences.
    Mohamed AF; Zhang J; Johnson FR; Lomon ID; Malvolti E; Townsend R; Ostgren CJ; Parhofer KG
    Diabetes Metab; 2013 Oct; 39(5):397-403. PubMed ID: 23880594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study.
    Hirji I; Grinspan J; Flood E; Chirovsky D; Devlen J; Wagner S; Davis C
    J Health Econ Outcomes Res; 2014; 2(1):75-86. PubMed ID: 37664084
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].
    Moro D; Schlander M; Telser H; Sola-Morales O; Clark MD; Olaye A; Camp C; Jain M; Butt T; Bakshi S
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):581-598. PubMed ID: 34877915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice Experiment.
    Donnan JR; Johnston K; Chibrikov E; Marra CA; Aubrey-Bassler K; Najafzadeh M; Nguyen H; Gamble JM
    Can J Diabetes; 2020 Feb; 44(1):6-13. PubMed ID: 31311729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.
    Morillas C; Feliciano R; Catalina PF; Ponte C; Botella M; Rodrigues J; Esmatjes E; Lafita J; Lizán L; Llorente I; Morales C; Navarro-Pérez J; Orozco-Beltran D; Paz S; Ramirez de Arellano A; Cardoso C; Tribaldos Causadias M
    Patient Prefer Adherence; 2015; 9():1443-58. PubMed ID: 26508841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
    Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
    Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
    Mühlbacher A; Bethge S
    Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment.
    Huang Y; Huang Q; Xu A; Lu M; Xi X
    Front Public Health; 2021; 9():782964. PubMed ID: 35178370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
    Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
    Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Education and patient preferences for treating type 2 diabetes: a stratified discrete-choice experiment.
    Janssen EM; Longo DR; Bardsley JK; Bridges JF
    Patient Prefer Adherence; 2017; 11():1729-1736. PubMed ID: 29070940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferences for Patients with Type 2 Diabetes Mellitus for Medications in Shandong Province, China: A Discrete Choice Experiment.
    Lv Y; Ren R; Tang C; Song K; Li S; Wang H
    Patient Prefer Adherence; 2022; 16():2335-2344. PubMed ID: 36046499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus.
    Lloyd A; Nafees B; Barnett AH; Heller S; Ploug UJ; Lammert M; Bøgelund M
    Clin Ther; 2011 Sep; 33(9):1258-67. PubMed ID: 21862132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.